![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC9A3 |
Gene summary for SLC9A3 |
![]() |
Gene information | Species | Human | Gene symbol | SLC9A3 | Gene ID | 6550 |
Gene name | solute carrier family 9 member A3 | |
Gene Alias | DIAR8 | |
Cytomap | 5p15.33 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P48764 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6550 | SLC9A3 | S014 | Human | Liver | HCC | 4.34e-20 | 4.44e-01 | 0.2254 |
6550 | SLC9A3 | S015 | Human | Liver | HCC | 6.67e-18 | 5.50e-01 | 0.2375 |
6550 | SLC9A3 | S016 | Human | Liver | HCC | 3.89e-23 | 5.22e-01 | 0.2243 |
6550 | SLC9A3 | S027 | Human | Liver | HCC | 3.40e-03 | 2.35e-01 | 0.2446 |
6550 | SLC9A3 | S028 | Human | Liver | HCC | 4.40e-18 | 5.47e-01 | 0.2503 |
6550 | SLC9A3 | S029 | Human | Liver | HCC | 1.31e-14 | 3.82e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:19026008 | Breast | Precancer | proton transmembrane transport | 39/1080 | 157/18723 | 4.18e-15 | 1.18e-12 | 39 |
GO:20012445 | Breast | Precancer | positive regulation of intrinsic apoptotic signaling pathway | 17/1080 | 58/18723 | 1.59e-08 | 1.12e-06 | 17 |
GO:20012356 | Breast | Precancer | positive regulation of apoptotic signaling pathway | 24/1080 | 126/18723 | 1.98e-07 | 1.01e-05 | 24 |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:00702933 | Breast | Precancer | renal absorption | 6/1080 | 17/18723 | 2.59e-04 | 3.83e-03 | 6 |
GO:00085445 | Breast | Precancer | epidermis development | 35/1080 | 324/18723 | 2.71e-04 | 3.96e-03 | 35 |
GO:00099136 | Breast | Precancer | epidermal cell differentiation | 23/1080 | 202/18723 | 1.43e-03 | 1.50e-02 | 23 |
GO:00434912 | Breast | Precancer | protein kinase B signaling | 23/1080 | 211/18723 | 2.53e-03 | 2.30e-02 | 23 |
GO:00158336 | Breast | Precancer | peptide transport | 27/1080 | 264/18723 | 2.84e-03 | 2.49e-02 | 27 |
GO:00347673 | Breast | Precancer | positive regulation of ion transmembrane transport | 19/1080 | 167/18723 | 3.60e-03 | 2.98e-02 | 19 |
GO:00071638 | Breast | Precancer | establishment or maintenance of cell polarity | 23/1080 | 218/18723 | 3.82e-03 | 3.06e-02 | 23 |
GO:00109596 | Breast | Precancer | regulation of metal ion transport | 37/1080 | 406/18723 | 4.07e-03 | 3.22e-02 | 37 |
GO:00020649 | Breast | Precancer | epithelial cell development | 23/1080 | 220/18723 | 4.28e-03 | 3.35e-02 | 23 |
GO:00228985 | Breast | Precancer | regulation of transmembrane transporter activity | 27/1080 | 278/18723 | 5.72e-03 | 4.11e-02 | 27 |
GO:00226049 | Breast | Precancer | regulation of cell morphogenesis | 29/1080 | 309/18723 | 6.88e-03 | 4.67e-02 | 29 |
GO:200123314 | Breast | IDC | regulation of apoptotic signaling pathway | 82/1434 | 356/18723 | 6.27e-20 | 5.93e-17 | 82 |
GO:009719314 | Breast | IDC | intrinsic apoptotic signaling pathway | 69/1434 | 288/18723 | 6.32e-18 | 2.99e-15 | 69 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC9A3 | deletion | Frame_Shift_Del | novel | c.1586delN | p.Asp529AlafsTer4 | p.D529Afs*4 | P48764 | protein_coding | TCGA-G9-7519-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | ||
SLC9A3 | SNV | Missense_Mutation | rs201704801 | c.931N>A | p.Ala311Thr | p.A311T | P48764 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SLC9A3 | SNV | Missense_Mutation | c.1564N>T | p.Arg522Trp | p.R522W | P48764 | protein_coding | deleterious(0) | possibly_damaging(0.65) | TCGA-BR-7851-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC9A3 | SNV | Missense_Mutation | c.1244N>A | p.Arg415His | p.R415H | P48764 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BR-8081-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC9A3 | SNV | Missense_Mutation | c.2479G>A | p.Ala827Thr | p.A827T | P48764 | protein_coding | tolerated_low_confidence(0.6) | benign(0) | TCGA-CG-4442-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC9A3 | SNV | Missense_Mutation | rs534607238 | c.766N>A | p.Val256Met | p.V256M | P48764 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CG-4444-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
SLC9A3 | SNV | Missense_Mutation | c.1006C>T | p.Arg336Cys | p.R336C | P48764 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-HU-A4GN-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | mitomycin | PD | |
SLC9A3 | SNV | Missense_Mutation | c.1624N>A | p.Asp542Asn | p.D542N | P48764 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-R5-A7O7-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SLC9A3 | SNV | Missense_Mutation | rs138322600 | c.1658N>A | p.Arg553His | p.R553H | P48764 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
SLC9A3 | SNV | Missense_Mutation | novel | c.2273N>T | p.Ser758Phe | p.S758F | P48764 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-VQ-A924-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | GLUCOCORTICOID | 9727362 | ||
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | AZD1722 | |||
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | inhibitor | CHEMBL2107782 | ||
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | AVE-0657 | |||
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | AZD1772//RDX5791 | |||
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | inhibitor | CHEMBL3301627 | TENAPANOR HYDROCHLORIDE | |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | RDX-5791 | TENAPANOR HYDROCHLORIDE | ||
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | ALBUMIN | ALBUMIN HUMAN | 11251045,11698229 |
Page: 1 |